Clesrovimab is a medicine that helps protect babies from serious lung infections caused by RSV. It gives the baby ready-made antibodies that stop the virus from getting into cells. It's given as a single shot into the muscle before or during the baby's first RSV season.
Every report comes from a Lived member, sent anonymously.
Have you tried Enflonsia (Clesrovimab) for Respiratory Syncytial Virus (RSV) Infection?
Clesrovimab, sold as Enflonsia, is a single injection given to babies to protect them from serious lung infections caused by respiratory syncytial virus (RSV). In older children and adults RSV usually causes a cold, but in young infants it can spread into the small airways and lungs, causing bronchiolitis or pneumonia. Before infant protection became routine in 2023, RSV was the leading cause of hospital stays among babies in the United States. The FDA approved clesrovimab in 2025 for newborns and infants who are born during, or are about to enter, their first RSV season, which in most of the continental US runs from fall through spring. It is used for healthy full-term babies as well as babies born early or with heart or lung conditions. US guidance offers three equally acceptable ways to protect a baby: an RSV vaccine (Abrysvo) given to the mother late in pregnancy, or one of two antibody shots given to the baby, clesrovimab or nirsevimab (Beyfortus). No one option is preferred, and most babies need only one of them. A baby born at least 14 days after the mother's RSV vaccination usually does not need an antibody shot. A baby whose mother was not vaccinated, whose vaccination status is unknown, or who was born less than 14 days after it should get one.
Antibodies are proteins the immune system uses to recognize and block germs. A newborn's own defenses take months to mature, so clesrovimab supplies ready-made antibodies instead. This is called passive immunity: the protection comes from the antibody in the injection itself, rather than from the baby's body learning to fight the virus, as happens after a vaccine. Clesrovimab is a monoclonal antibody, a lab-made antibody designed to attach to one specific target. It binds to the F (fusion) protein on the surface of RSV, which the virus needs to merge with and enter the cells lining the airways. With that step blocked, the virus has a much harder time taking hold in the lungs. The antibody has also been engineered to last longer in the body than a typical antibody, which is why one dose can cover a whole season. Antibody levels rise within hours, peak in about a week, then slowly decline over the following months.
Clesrovimab is given once, as a shot into the thigh muscle, by a doctor, nurse or other healthcare provider. Every baby receives the same dose (105 mg), regardless of weight, and there is nothing to give at home. Timing depends on when the baby is born. In most of the continental US, babies born between October and March should receive it within their first week of life, ideally before leaving the hospital after birth. Babies born from April through September are usually given it starting in October, shortly before RSV season, so that protection is strongest when the virus is most common. Health departments may shift these months in places where RSV follows a different pattern, such as Alaska or tropical areas. A baby who has heart surgery using a heart-lung bypass machine during or just before the first RSV season gets a second dose once stable after surgery, to restore antibody levels the procedure lowers. Clesrovimab can be given at the same visit as routine childhood vaccines, in a different spot on the body.
Most babies have no noticeable reaction. In the main trial, the most common effects were redness or swelling where the shot was given and a mild rash, each affecting a few percent of babies and occurring nearly as often in babies who received a placebo (salt water) shot. Fussiness and sleepiness were also commonly reported. Nearly all reactions were mild or moderate. Over the following year, serious health problems were no more common in babies who received clesrovimab than in those who received placebo. Let the care team know if redness or swelling at the injection site is severe or does not go away. A serious allergic reaction is rare but possible, as with other antibody medicines. Call 911 if a baby develops swelling of the face, lips or tongue, trouble breathing or swallowing, or bluish skin or lips after the shot. Hives or a spreading rash soon after the injection should prompt a call to the care team right away.
Clesrovimab should not be given to a baby who has had a serious allergic reaction, such as anaphylaxis, to it or any of its ingredients. Tell the care team about any past reactions to medicines. The antibody can cause a falsely negative result on some rapid RSV tests, the quick swab tests often done in clinics. If a baby who has received clesrovimab has symptoms that look like RSV, clinicians are advised to confirm with a PCR (polymerase chain reaction) test, a more sensitive laboratory test that the antibody does not affect. It helps to mention the shot whenever a baby is tested for a respiratory illness. Clesrovimab and nirsevimab do the same job, so a baby needs only one dose of one of them for the first season. Clesrovimab does not interfere with routine childhood vaccines.
The injection takes only a moment, and protection begins within hours of the shot and is strongest after about a week. In clinical trials a single dose protected for at least 5 months, long enough to cover a typical RSV season. The benefit is substantial but not complete. In the main trial of healthy babies born at 29 weeks of pregnancy or later, those who received clesrovimab had about 60% fewer RSV chest infections needing medical care over 5 months than babies given a placebo, and about 85 to 90% fewer RSV hospital stays. In babies at higher risk because they were born early or had chronic lung or heart disease, infection and hospitalization rates were similar to those with palivizumab, an older antibody that had to be given every month. A protected baby can still catch RSV, but serious illness needing a hospital stay is much less likely. The antibody protects only against RSV, not against flu or other respiratory viruses. Most babies need only this one dose. Clesrovimab is approved only for the first RSV season. Children aged 8 to 19 months who remain at high risk for severe RSV going into their second season may be offered another antibody dose, and for that situation the CDC currently recommends nirsevimab (Beyfortus) rather than clesrovimab.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Enflonsia (Clesrovimab), what you've noticed, or ask the community a question.